Boehringer Ingelheim GmbH

vorige Seite Seite 1 von 5 nächste Seite

Boehringer Ingelheim und die Vanderbilt University erweitern ihre Partnerschaft zur Entwicklung neuartiger Behandlungsansätze gegen Krebs

Boehringer Ingelheim und die Vanderbilt University gaben heute die Erweiterung ihrer erfolgreichen, bestehenden Zusammenarbeit bei der Entwicklung neuartiger Wirkstoffe gegen Krebs bekannt.

13.03.2018 16:46
27.09.2014 09:03

Boehringer Ingelheim vollzieht Akquisition der Amgen Fremont Produktionsstätte in den USA

Boehringer Ingelheim hat heute die Akquisition derbiopharmazeutischen Entwicklungs- und Produktionsstätte von Amgen in Fremont, Kalifornien (USA), formell abgeschlossen.

25.03.2011 18:57

Boehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer

Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian …

17.12.2009 13:35

Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

- Results Support Flibanserin as a Potential Treatment for HSDD, an Under-Recognised Women's Sexual Health Condition

16.11.2009 14:20

Boehringer Ingelheim Receives Approval From the European Commission for Mirapexin(R)/Sifrol(R) Prolonged-Release, Once Daily Tablet for the Treatment of Parkinson's Disease

- New Formulation Brings the Established Efficacy of Mirapexin(R)/Sifrol(R) to Patients With Parkinson's Disease in the Convenience of a Once Daily Dose

14.10.2009 09:10

Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 (Tovok(TM)) as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Mutations

- Data From Phase II Studies Investigating BIBW 2992 (Tovok(TM)) and BIBF 1120 (Vargatef(TM)) in NSCLC Patients Presented at 13th World Conference on Lung Cancer (WCLC)

03.08.2009 07:06
06.07.2009 12:12

New Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results

- Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting

06.06.2009 17:08
27.05.2009 12:37

Outcome of New Mirapexin(R)/Sifrol(R) (Pramipexole) Study set to Change Treatment of Depressive Symptoms in Parkinson's Disease

- New Study Shows That Mirapexin(R)/Sifrol(R) (Pramipexole) Relieves Depressive Symptoms of Parkinson's Disease (PD), a Common Non-Motor Symptom Affecting PD Patients' Quality of Life

30.04.2009 08:14
vorige Seite nächste Seite